Drug target · APP

Amyloid-beta (aggregated)

Amyloid-beta peptide (APP-derived) — solanezumab binds the soluble monomeric species

3 compounds in the CNS pipeline act on Amyloid-beta (aggregated).

Compounds targeting Amyloid-beta (aggregated)

CompoundActionAffinityLead programDeveloper
CrenezumabprimaryBiologicInhibitor—DiscontinuedAlzheimer's diseaseAC Immune SA
GantenerumabprimaryBiologicInhibitorKd 0.6 nMDiscontinuedAlzheimer's diseaseF. Hoffmann-La Roche Ltd
SolanezumabprimaryBiologicInhibitor—DiscontinuedAlzheimer's diseaseEli Lilly and Company